Navigation Links
Study examines reasons patients with early stage lung cancer do not have surgery
Date:6/15/2010

Despite a greater likelihood of poorer outcomes, many patients newly-diagnosed with early-stage lung cancer do not undergo surgery. New research indicates that among the factors associated with this decision include misunderstandings of the prognosis, negative perceptions of patient-physician communication and older age, with black patients more likely to not have surgery, according to a study in the June 16 issue of JAMA.

Lung cancer is the leading cause of cancer death in the United States. "Surgical resection for stage I or II non-small cell cancer remains the only reliable treatment for cure. Patients who do not undergo surgery have a median [midpoint] survival of less than 1 year. Despite the survival disadvantage, many patients with early-stage disease do not receive surgical care and rates are even lower for black patients," the authors write.

Samuel Cykert, M.D., of the Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, N.C., and colleagues conducted a study among newly diagnosed patients with early-stage lung cancer to identify potentially modifiable factors regarding undergoing surgery and to explore why black patients have this surgery less than white patients. The study included 437 patients with biopsy-proven or probable early-stage lung cancer, who were enrolled between December 2005 and December 2008. Before determining treatment plans, patients were administered a survey including questions about trust, patient-physician communication, attitudes toward cancer and functional status. Information about co-existing illnesses was obtained through examination of charts. A total of 386 patients met eligibility criteria for lung resection surgery. The median age was 66 years and 29 percent of patients were black. Two hundred forty-one patients (62 percent) had lung cancer surgery within 4 months of diagnosis (179/273 white patients [66 percent] vs. 62/113 black patients [55 percent]).

"Potentially reversible factors associated with omitting cancer surgery included (1) a patient's belief that the lung cancer diagnosis was less than 90 percent certain, (2) a feeling that overall quality of life would be worse in 1 year because of lung cancer surgery, and (3) patients' perception of lower-quality cancer communication manifested by a 5-point decrement on a 25-point communication scale," the authors write.

The researchers also found that black patients with 2 or more co-existing illnesses had a lower likelihood of surgery, compared to those with less than 2 co-existing illnesses, 13 percent vs. 62 percent, respectively. Surgical rates were also low for black patients when they lacked a regular source of care (42 percent with no regular care vs. 57 percent with regular care), and lower income was associated with fewer surgeries for white patients.

"We found that patients' negative perceptions about the communication process and misperceptions of quality of life 1 year after lung cancer diagnosis were related to lower surgical rates in everyone. These results suggest the need for preoperative discussions that pay close attention to the prognosis for functional and pulmonary recovery after surgery compared with expected cancer progression without intervention," the researchers write.

(JAMA. 2010;303[23]:2368-2376. Available pre-embargo to the media at www.jamamedia.org)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.


Editorial: Racial Disparities in Lung Cancer Resection

In an accompanying editorial, Gene L. Colice, M.D., of the Washington Hospital Center and George Washington University, Washington, D.C., comments on the findings of this study.

"The report by Cykert et al reaffirms the disturbing fact that blacks with stage I or II non-small cell lung cancer are less likely than whites to undergo potentially curative surgical resection, and also provides important and somewhat unsettling insights into how stage I or II non-small cell lung cancer is managed in a diverse U.S. community. Besides concentrating on ways to improve communication between clinicians and black patients, attention should be directed at establishing minimal community performance standards for managing non-small cell lung cancer. These essential steps should be in place if and when an effective lung cancer screening tool becomes available."

(JAMA. 2010;303[23]:2411-2412. Available pre-embargo to the media at www.jamamedia.org)

Editor's Note: Please see the article for additional information, including financial disclosures, funding and support, etc.


'/>"/>

Contact: Tom Hughes
tahughes@unch.unc.edu
919-966-6047
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. Casual Sex Doesnt Cause Emotional Damage: Study
2. Study Finds Possible Explanation for the Link Between Infertility and Breast/Ovarian Cancer Risks
3. Screening for Spinal Muscular Atrophy Not Cost-Effective: Study
4. New study finds possible source of beta cell destruction that leads to Type 1 diabetes
5. New Study Demonstrates Novel Use of Metabolic Imaging to Locate Sperm in Infertile Men -- Non-Invasive Imaging Procedure May Replace Invasive Techniques such as Testicula
6. Risk of stroke lower for recent Ontario immigrants: study
7. Definitive study confirms chemo benefit in postmenopausal breast cancer
8. Experimental stem cell treatment arrests acute lung injury in mice, study shows
9. Violence is part of the job say nurses as study shows only 1 in 6 incidents are reported
10. Controversial Autism Study Retracted by Medical Journal
11. Study Reveals Impact Of Health Insurance On Hispanics' Attitudes Towards Healthcare Providers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , Ginger Pigott ... LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport Beach ... from the firm’s global Life Sciences & Medical Technology Group have been featured speakers ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged to ... mind, SIGVARIS has created a new line of anti-embolism stockings to help prevent ... the benefits of graduated compression when transitioning from recovery to early rehabilitation. , ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... and financial planning services from offices headquartered in Hamilton County, is embarking on ... LuvFurMutts. , LuvFurMutts specializes in finding new homes for orphaned or neglected senior ...
(Date:12/8/2016)... , ... December 08, 2016 , ... The Compretta Insurance ... and residential clients in and around the Hancock County area, is announcing the launch ... County Food Pantry. , The Hancock County Food Pantry has worked for more than ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)...  Pennsylvania Physician General Dr. Rachel Levine ... Gary Tennis released safe prescribing guidelines ... developed with the help of a task force. ... frequently prescribed for anxiety or insomnia," said Dr. ... pain medications, benzodiazepines pose a significant risk for ...
(Date:12/8/2016)... Information products and services provider Elsevier has launched ... world,s largest abstract and citation database of peer-reviewed literature, providing the ... 5,000 publishers. The new set of metrics will improve decisions on ... adjust a journal,s editorial strategy. ... , CiteScore metrics comprise ...
(Date:12/8/2016)... , December 8, 2016 According ... Diabetes Injection Pens Market is expected to be worth ... US$4.9 bn in 2015. Between the forecast years of 2016 ... a CAGR of 7.9%. The leading players operating in the ... Lilly and Company, AstraZaneca plc., Biocon Ltd., and Sanofi S.A. ...
Breaking Medicine Technology: